THE OVERALL OBJECTIVE OF THIS RESEARCH IS TO EVALUATE THE POTENTIAL EFFICACY OF HORMONOCONJUGATE THERAPY FOR MELANOMA.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
4771
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Piedmont Research Company
3508 University Drive Suite 2, Durham, NC, 27707
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
GARY M STUHLMILLER
PRINCIPAL INVESTIGATOR
(919) 968-0433
Business Contact:
() -
Research Institution:
n/a
Abstract
THE OVERALL OBJECTIVE OF THIS RESEARCH IS TO EVALUATE THE POTENTIAL EFFICACY OF HORMONOCONJUGATE THERAPY FOR MELANOMA.RESEARCHERS WILL CONJUGATE SEVERAL DIFFERENT PROTEINS OR OR PEPTIDES TO THE HORMONE MSH AND ATTEMPT TO DELIVER THESE TO MURINE B16 MELANOMA. THE GOAL IS TO USE MSH AS A VEHICLEFOR DELIVERING AN IMMUNOGENIC MOLECULE TO THE B16 CELL MEMBRANE, THEREBY PROVIDING A TARGET FOR IMMUNE DESTRUCTION OF THE TUMOR CELLS. TO ACCOMPLISH THIS, THE CONJUGATES WILLBE SYNTHESIZED AND THEIR ACTIVITY EXAMINED IN VITRO. CONJUGATES THAT RETAIN RECEPTOR BINDING ACTIVITY WILL NEXT BE EVALUATED FOR THEIR IMMUNOGENICITY AND FOR THEIR ABILITY TO LOCALIZE TO B16 CELLS IN VIVO. FINALLY, APPROPRIATE CONJUGATES WILL BE USED FOR IN SITU MANIPULATION OF THE IMMUNOGENICITY OF B16 CELLS. SATISFACTORY COMPLETION OF THIS RESEARCH SHOULD LEAD INTO THE DEVELOPMENT OF SINGLE- AGENT THERAPY FOR MELANOMA.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government